Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D1-Like receptors

被引:50
作者
Yasunari, K [1 ]
Kohno, M [1 ]
Kano, H [1 ]
Minami, M [1 ]
Yoshikawa, J [1 ]
机构
[1] Osaka City Univ, Sch Med, Dept Internal Med 1, Osaka 5458586, Japan
关键词
catecholamines; muscle; smooth; atherosclerosis; receptors; hypertension; kidney;
D O I
10.1161/01.CIR.101.19.2302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - To elucidate the roles of vascular D-1-like receptors in atherosclerosis, the effects of the specific D-1-like agonists on platelet-derived growth factor (PDGF)-BB-mediated oxidative stress in vascular smooth muscle cells (VSMCs) were studied. Methods and Results - Immunohistochemical studies demonstrated the coexistence of D-1A and D-1B dopamine receptors in VSMCs. Western blotting revealed a band of approximate to 70 kDa for D-1A and D-1B dopamine receptors. VSMCs stimulated by PDGF-BB exhibited increased oxidative stress directly measured by flow cytometry. These effects were prevented by dopamine, SKF 38393, or YM 435, and this prevention was reversed by Sch 23390. These effects were blocked by a specific protein kinase A (PKA) inhibitor, N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide (H 89). The PDGF-BB-mediated increase in oxidative stress of VSMCs was significantly suppressed by the indirect phospholipase D (PLD) inhibitor suramin or the specific protein kinase C (PKC) inhibitor calphostin C. Both antisense but neither sense nor scrambled oligonucleotides to D-1A and D-1B receptors inhibited dopamine-induced suppression of increase in oxidative stress of VSMCs induced by PDGF-BB. Conclusions - These findings suggest that vascular D-1-like receptors (D-1A and D-1B receptors) inhibit any increase in oxidative stress of VSMCs, possibly through activation of PKA and suppression of PLD and PKC.
引用
收藏
页码:2302 / 2308
页数:7
相关论文
共 18 条
[1]   Role of the D-1A dopamine receptor in the pathogenesis of genetic hypertension [J].
Albrecht, FE ;
Drago, J ;
Felder, RA ;
Printz, MP ;
Eisner, GM ;
Robillard, JE ;
Sibley, DR ;
Westphal, HJ ;
Jose, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (10) :2283-2288
[2]  
APOSTOLAKIS EM, 1996, J NEUROSCI, V16, P4923
[3]   RECENT ADVANCES IN THE MOLECULAR-BIOLOGY OF DOPAMINE-RECEPTORS [J].
GINGRICH, JA ;
CARON, MG .
ANNUAL REVIEW OF NEUROSCIENCE, 1993, 16 :299-321
[4]   Reactions of H-2 with the nickel site(s) of the [FeNi] and [FeNiSe] hydrogenases: What do the model complexes suggest? [J].
Goldman, CM ;
Mascharak, PK .
COMMENTS ON INORGANIC CHEMISTRY, 1995, 18 (01) :1-25
[5]   THIOL-GROUP IDENTIFICATION AT OR NEAR THE AGONIST BINDING-SITE OF THE VASCULAR DOPAMINE RECEPTOR [J].
HALL, AS ;
ERROL, C ;
BRYSON, SE ;
BALL, SG ;
BALMFORTH, AJ .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 226 (03) :253-258
[6]   FREE AND CONJUGATED PLASMA-CATECHOLAMINES IN HYPERTENSIVE PATIENTS WITH AND WITHOUT PHEOCHROMOCYTOMA [J].
KUCHEL, O ;
BUU, NT ;
FONTAINE, A ;
HAMET, P ;
BERONIADE, V ;
LAROCHELLE, P ;
GENEST, J .
HYPERTENSION, 1980, 2 (02) :177-186
[7]   Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease [J].
Offen, D ;
Ziv, I ;
Sternin, H ;
Melamed, E ;
Hochman, A .
EXPERIMENTAL NEUROLOGY, 1996, 141 (01) :32-39
[8]   Expression of the subtype 1A dopamine receptor in the rat heart [J].
Ozono, R ;
OConnell, DP ;
Vaughan, C ;
Botkin, SJ ;
Walk, SF ;
Felder, RA ;
Carey, RM .
HYPERTENSION, 1996, 27 (03) :693-703
[9]  
PRESCOTT MF, 1991, AM J PATHOL, V139, P1291
[10]   ACTIVE OXYGEN SPECIES STIMULATE VASCULAR SMOOTH-MUSCLE CELL-GROWTH AND PROTOONCOGENE EXPRESSION [J].
RAO, GN ;
BERK, BC .
CIRCULATION RESEARCH, 1992, 70 (03) :593-599